Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2223]

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients with GIST previously treated with imatinib

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients...

How has the COVID-19 pandemic impacted clinicians who care for children with cancer?

How has the COVID-19 pandemic impacted clinicians who care for children with cancer?

Lung cancer screening among non-smoking women in Taiwan led to overdiagnosis

Lung cancer screening among non-smoking women in Taiwan led to overdiagnosis

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC previously treated with sorafenib

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC...

First-in-human trial with CAR macrophages shows the cell therapy may be safe, feasible for solid tumours

First-in-human trial with CAR macrophages shows the cell therapy may be safe, feasible for solid tumours

Protecting people with cancer from COVID-19: New recommendations from cancer guidelines organisation

Protecting people with cancer from COVID-19: New recommendations from cancer guidelines organisation

Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma

Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma

Late diagnosis has created a deadly cancer gap in the UK

Late diagnosis has created a deadly cancer gap in the UK

Practical tools and guidelines for young oncologists from resource-limited settings to publish excellence and advance their career

Practical tools and guidelines for young oncologists from resource-limited settings to publish excellence and...

ICR responds to NICE decision not to recommend olaparib for advanced prostate cancer

ICR responds to NICE decision not to recommend olaparib for advanced prostate cancer

More from ecancer